Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Rapid Micro Biosystems Inc (RPID)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: RPID (3-star) is a STRONG-BUY. BUY since 33 days. Profits (22.60%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
3 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Year Target Price $8
Year Target Price $8
| 3 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit 124.49% | Avg. Invested days 34 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 156.92M USD | Price to earnings Ratio - | 1Y Target Price 8 |
Price to earnings Ratio - | 1Y Target Price 8 | ||
Volume (30-day avg) - | Beta 1.34 | 52 Weeks Range 0.58 - 4.04 | Updated Date 06/29/2025 |
52 Weeks Range 0.58 - 4.04 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.03 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -151.22% | Operating Margin (TTM) -161.85% |
Management Effectiveness
Return on Assets (TTM) -27.74% | Return on Equity (TTM) -52.3% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 119808537 | Price to Sales(TTM) 5.29 |
Enterprise Value 119808537 | Price to Sales(TTM) 5.29 | ||
Enterprise Value to Revenue 4.04 | Enterprise Value to EBITDA 0.82 | Shares Outstanding 39332200 | Shares Floating 19102732 |
Shares Outstanding 39332200 | Shares Floating 19102732 | ||
Percent Insiders 10.66 | Percent Institutions 60.54 |
Analyst Ratings
Rating 5 | Target Price 8 | Buy - | Strong Buy 3 |
Buy - | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Rapid Micro Biosystems Inc
Company Overview
History and Background
Rapid Micro Biosystems, Inc. (RPID) was founded in 2006 and is headquartered in Lowell, Massachusetts. The company focuses on developing and commercializing innovative automated microbial detection and enumeration technologies for biopharmaceutical manufacturing.
Core Business Areas
- Automated Microbial Detection: RPID provides systems that automate and accelerate the detection of microbial contamination in biopharmaceutical manufacturing processes. This includes rapid growth direct detection and enumeration of microorganisms.
Leadership and Structure
Robert Spignesi serves as the Chief Executive Officer. The company operates with a functional organizational structure, focusing on R&D, manufacturing, sales, and marketing, supporting its core business.
Top Products and Market Share
Key Offerings
- Growth Direct System: The Growth Direct System automates and accelerates microbial detection and enumeration in pharmaceutical manufacturing. It automates the traditional manual methods and reduces testing time. Market share data is not readily available publicly. Competitors include Charles River Laboratories (CRL), bioMu00e9rieux (BIM.PA), and MilliporeSigma.
Market Dynamics
Industry Overview
The biopharmaceutical microbial testing market is driven by stringent regulatory requirements and the increasing complexity of biopharmaceutical manufacturing. There is demand for faster and more reliable microbial detection methods.
Positioning
Rapid Micro Biosystems is positioned as an innovative provider of automated microbial detection systems that accelerate the microbial testing workflow in the biopharmaceutical industry, offering significant time savings and improved data accuracy.
Total Addressable Market (TAM)
The total addressable market for automated microbial detection in biopharmaceutical manufacturing is estimated to be in the billions of dollars. Rapid Micro Biosystems is well-positioned to capture a significant share of this market by providing solutions that address the evolving needs of biopharmaceutical manufacturers.
Upturn SWOT Analysis
Strengths
- Automated technology
- Faster time to results
- Improved data accuracy
- Strong industry partnerships
Weaknesses
- Limited financial resources
- High dependence on key product
- Relatively small market share
- Customer adoption rates
Opportunities
- Expansion into new geographic markets
- Development of new product applications
- Strategic acquisitions
- Partnerships with other industry players
Threats
- Competition from larger companies
- Technological obsolescence
- Changing regulatory requirements
- Economic downturns
Competitors and Market Share
Key Competitors
- CRL
- bioMu00e9rieux.PA
Competitive Landscape
RPID competes with larger companies that have greater financial resources and broader product portfolios. RPID's advantage lies in its innovative automated technology and focus on biopharmaceutical manufacturing.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been steady, driven by adoption of the Growth Direct System.
Future Projections: Future growth is projected to be driven by increased adoption of automated microbial testing technologies in the biopharmaceutical industry.
Recent Initiatives: Recent initiatives include new product development and strategic partnerships to expand market reach.
Summary
Rapid Micro Biosystems is a specialized company in automated microbial detection, particularly for biopharmaceutical manufacturing. Its Growth Direct system offers significant time savings compared to traditional methods, but adoption speed is key to growth. Competition from larger players like Charles River Laboratories is a constant challenge. Its innovative technology needs to continuously evolve to maintain its competitive advantage.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Market Research Reports
- Financial News Outlets
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Market share data is based on estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Rapid Micro Biosystems Inc
Exchange NASDAQ | Headquaters Lexington, MA, United States | ||
IPO Launch date 2021-07-15 | CEO, President & Director Mr. Robert G. Spignesi Jr. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 163 | Website https://www.rapidmicrobio.com |
Full time employees 163 | Website https://www.rapidmicrobio.com | ||
Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in the United States, Germany, Switzerland, Japan, and internationally. The company offers Growth Direct platform, which includes growth direct system, proprietary consumables, lab information management system connection software, and customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides onsite technical training services. Its solutions are used in environmental monitoring, water, bioburden, and sterility release testing applications. In addition, the company offers RMBNucleus Mold Alarm software; and Growth Direct LIMS connection software. Rapid Micro Biosystems, Inc. was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.